Letter to the editor

DOI: 10.4244/EIJ-D-24-00560

Letter: Identifying vulnerable coronary atherosclerotic plaques: from theory to practice

Kyriakos Dimitriadis1, MD, PhD, FESC; Nikolaos Pyrpyris, MD; Konstantinos Tsioufis, MD, PhD, FESC

We read with great interest the study by del Val et al1 regarding the prognostic role of vulnerable plaque features in non-ischaemic lesions, showing thin-cap fibroatheroma (TCFA) as the strongest predictor of future events, with the addition of other vulnerable plaque parameters further increasing this risk. This study is of particular importance; however, several key insights must be highlighted.

Firstly, 68.4-84.4% of patients received statins, with significantly lower use in most subgroups with high-risk characteristics, compared to patients without. Furthermore, there is no report of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor use. It is well documented that PCSK9 inhibitors lead to plaque regression and stabilisation2. Notably, a phenotype of “triple regression” − which consists of the combined presence of (a) percentage of atheroma volume reduction, (b) maximum lipid core burden index within 4 mm reduction and (c) minimal fibrous cap thickness increase − is significantly associated with fewer adverse outcomes and independently associated with the use of PCSK9 inhibitors3. Given the prognostic significance of both vulnerable plaques and the presence of plaque regression, as well as the...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 16
Aug 19, 2024
Volume 20 Number 16
View full issue


Key metrics

Suggested by Cory

Debate

10.4244/EIJ-E-24-00004 Mar 4, 2024
Prophylactic stenting of vulnerable plaques: pros and cons
Park D et al
free

Viewpoint

10.4244/EIJ-D-22-00397 Oct 21, 2022
Skating on thin ice: searching for vulnerable plaques
Prati F et al
free

Jan 15, 2010
Triple therapy: the future or from the past?
Dewilde W et al
free

Editorial

10.4244/EIJ-E-22-00051 Jan 23, 2023
What makes a plaque rupture? A simple answer seems too much to ask for
Achenbach S
free

Clinical research

10.4244/EIJ-D-22-00562 Jan 23, 2023
Outcomes of non-ischaemic coronary lesions with high-risk plaque characteristics on coronary CT angiography
Yang S et al
free

Editorial

10.4244/EIJ-E-25-00018 Jun 2, 2025
Using pericoronary fat attenuation to guide management after coronary interventions
Antoniades C and Chan K
free
Trending articles
172.05

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
79.3

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
42

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved